Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).

Area of Science:

• Immunology
• Molecular Biology

Background:

• Type I interferons (IFNs), especially IFN-α, are recognized as central mediators in the pathogenesis of immune-mediated inflammatory diseases (IMIDs).
• IMIDs include systemic lupus erythematosus (SLE), systemic sclerosis, inflammatory myositis, and Sjögren's syndrome, all influenced by aberrant innate immunity.

Approach:

• Reviewing pharmacological strategies to target type I IFNs and their downstream signaling pathways for IMID treatment.
• Exploring monoclonal antibodies against IFNs or IFN-receptors (IFNARs), such as anifrolumab.
• Investigating inhibitors of downstream signaling molecules like JAK1 and Tyk2.

Key Points:

• Anifrolumab, a monoclonal antibody targeting IFN-α, is approved for treating SLE.
• JAK1 and Tyk2 inhibitors are in Phase III clinical trials for SLE, demonstrating progress in targeting IFN pathways.
• Type I IFN targeting is an established treatment for SLE and shows potential for other IMIDs.

Conclusions:

• Targeting type I IFNs is a validated therapeutic strategy for SLE and is emerging as a promising approach for other IMIDs.
• Further validation of IFN assays and development of targeted therapies will integrate these approaches into routine clinical practice for IMIDs.